Charles Schwab
EDIT icon

Charles Schwab’s Editas Medicine EDIT Stock Holding History

Charles Schwab’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Buy
868,032
+6,706
+0.8% +$19.6K ﹤0.01% 2671
2026
Q1 		$2.13M Buy
861,326
+66,655
+8% +$141K ﹤0.01% 2705
2025
Q4 		$1.63M Buy
794,671
+14,716
+2% +$42.5K ﹤0.01% 2793
2025
Q3 		$2.71M Buy
779,955
+78,450
+11% +$219K ﹤0.01% 2677
2025
Q2 		$1.54M Buy
701,505
+16,609
+2% +$27.2K ﹤0.01% 2750
2025
Q1 		$794K Buy
684,896
+76,647
+13% +$113K ﹤0.01% 2919
2024
Q4 		$772K Sell
608,249
-9,031
-1% -$23K ﹤0.01% 2998
2024
Q3 		$2.1M Sell
617,280
-116,105
-16% -$505K ﹤0.01% 2696
2024
Q2 		$3.42M Sell
733,385
-122,710
-14% -$692K ﹤0.01% 2521
2024
Q1 		$6.35M Buy
856,095
+172,079
+25% +$1.43M ﹤0.01% 2199
2023
Q4 		$6.93M Sell
684,016
-4,948
-0.7% -$43.4K ﹤0.01% 2174
2023
Q3 		$5.37M Buy
688,964
+170,694
+33% +$1.46M ﹤0.01% 2219
2023
Q2 		$4.27M Buy
518,270
+4,920
+1% +$42.9K ﹤0.01% 2293
2023
Q1 		$3.72M Buy
513,350
+3,591
+0.7% +$31.9K ﹤0.01% 2331
2022
Q4 		$4.52M Buy
509,759
+10,303
+2% +$113K ﹤0.01% 2262
2022
Q3 		$6.11M Buy
499,456
+12,628
+3% +$197K ﹤0.01% 2112
2022
Q2 		$5.76M Sell
486,828
-10,746
-2% -$144K ﹤0.01% 2127
2022
Q1 		$9.46M Buy
497,574
+12,788
+3% +$238K ﹤0.01% 1989
2021
Q4 		$12.9M Buy
484,786
+9,699
+2% +$334K ﹤0.01% 1869
2021
Q3 		$19.5M Sell
475,087
-18,048
-4% -$989K 0.01% 1604
2021
Q2 		$27.9M Buy
493,135
+12,097
+3% +$447K 0.01% 1307
2021
Q1 		$20.2M Buy
481,038
+68,350
+17% +$3.89M 0.01% 1520
2020
Q4 		$28.9M Buy
412,688
+5,036
+1% +$207K 0.01% 1132
2020
Q3 		$11.4M Buy
407,652
+13,935
+4% +$454K 0.01% 1600
2020
Q2 		$11.6M Buy
393,717
+57,361
+17% +$1.5M 0.01% 1551
2020
Q1 		$6.67M Buy
336,356
+20,355
+6% +$513K ﹤0.01% 1688
2019
Q4 		$9.36M Buy
316,001
+16,818
+6% +$420K 0.01% 1697
2019
Q3 		$6.8M Buy
299,183
+30,646
+11% +$759K ﹤0.01% 1818
2019
Q2 		$6.64M Buy
268,537
+14,515
+6% +$346K ﹤0.01% 1834
2019
Q1 		$6.21M Buy
254,022
+11,392
+5% +$258K ﹤0.01% 1873
2018
Q4 		$5.52M Sell
242,630
-226
-0.1% -$6.15K ﹤0.01% 1857
2018
Q3 		$7.73M Buy
242,856
+28,891
+14% +$934K 0.01% 1799
2018
Q2 		$7.67M Buy
213,965
+29,981
+16% +$1.06M 0.01% 1768
2018
Q1 		$6.1M Buy
183,984
+46,209
+34% +$1.65M ﹤0.01% 1831
2017
Q4 		$4.23M Buy
137,775
+20,763
+18% +$523K ﹤0.01% 2008
2017
Q3 		$2.81M Buy
117,012
+18,366
+19% +$350K ﹤0.01% 2146
2017
Q2 		$1.66M Buy
98,646
+56,496
+134% +$1.02M ﹤0.01% 2286
2017
Q1 		$941K Buy
42,150
+3,249
+8% +$67.3K ﹤0.01% 2445
2016
Q4 		$632K Buy
38,901
+2,926
+8% +$44.4K ﹤0.01% 2578
2016
Q3 		$485K Buy
35,975
+16,610
+86% +$340K ﹤0.01% 2623
2016
Q2 		$473K Buy
19,365
+10,594
+121% +$357K ﹤0.01% 2606
2016
Q1 		$303K Buy
+8,771
New +$231K ﹤0.01% 2772

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Charles Schwab's EDIT Position: Q2 2026 in Review

Charles Schwab increased its Editas Medicine (EDIT) stake by 0.78% in Q2 2026, buying an estimated $19.6K and bringing the position to 868,032 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2671.

Charles Schwab first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $28.9M in Q4 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Charles Schwab held 868,032 shares of Editas Medicine worth $2.81M as of Q2 2026.
  • Charles Schwab bought 6,706 Editas Medicine shares in Q2 2026, an estimated $19.6K.
  • Editas Medicine made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2671 holding.
  • Charles Schwab first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Charles Schwab's Editas Medicine position peaked at $28.9M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.